Genomtec S.A.

Regulatory Filings • May 10, 2021

Patent protection has been granted for a set of primers foramplifying the nucleotide sequence of Borrelia burgdorferi, a method fordetecting Borrelia burgdorferi, a method for diagnosing Lyme disease anda kit for diagnosing Lyme disease.The Executive Board ofGenomtec S.A. ("Company", "Issuer") registered in Wroclaw, Poland,hereby reports that today the Company obtained patent document issued bythe Polish Patent Office on 23 March 2021. The title of the Patent is"Primers for amplifying the nucleotide sequence of Borrelia burgdorferi,a method for detecting Borrelia burgdorferi, a method for diagnosingLyme disease and a kit for diagnosing Lyme disease ".Themost common zoonosis (disease or infection which is likely to benaturally transmitted from animals to man) in Poland is Lyme diseasecaused by spirochetes of the genus Borrelia burgdorferi. Non-specificsystemic symptoms and varied clinical presentation as well as problemsin laboratory diagnostics often cause difficulties in the diagnosis ofLyme disease. In clinical practice, it is important to detect an earlystage of the disease, which is possible thanks to the Issuer's invention.TheIssuer informs that this is the second patent granted by the PatentOffice of the Republic of Poland and the third patent received by theCompany. The Issuer has pending twenty patent applications all over theworld.The Issuer's Management Board decided that the receipt ofthe above patent is confidential information, as in the case of anentity operating on the molecular diagnostics market, it is necessary toeffectively protect intellectual property and designs. Properly securedintellectual property and designs may constitute the Issuer'scompetitive advantage, allowing safer commercialization under conditionthat full protection is ensured on selected markets.In theopinion of the Management Board, a high degree of intellectual propertyprotection will also provide the Company with an appropriate negotiatingposition before signing commercial contracts with selected partners inthe scope of implementing the commercialization strategy.Patentproceedings are aimed at securing key interests and are in line with theIssuer's development strategy, which includes building a portfolio ofintellectual property rights. Diagnostics of bacterial infections,including Lyme infections, is one of the key areas of technologydeveloped by the Issuer. For these reasons, in the opinion of theManagement Board, this information meets the criteria of confidentialinformation within the meaning of Art. 7 sec. 1 MAR.